iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
September 27, 2023 16:19 ET
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the...
iBio Announces Amendment to Credit Agreement with Woodforest
September 21, 2023 16:05 ET
|
iBio, Inc.
– Extends maturity date to December 31, 2023 –– Allows time to close pending sale of CDMO facility –BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or...
iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
August 14, 2023 16:15 ET
|
iBio, Inc.
– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets – BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
June 27, 2023 08:00 ET
|
iBio, Inc.
– Board appointments solidify management team to lead iBio’s AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the...
iBio Forges Research Collaboration with the National Institutes of Health
June 12, 2023 16:15 ET
|
iBio, Inc.
– NIH to evaluate iBio’s patented AI-driven epitope steering platform for Lassa fever vaccine development – BRYAN, Texas and SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
iBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline
June 06, 2023 08:00 ET
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced the expansion of its AI-powered technology stack with the launch of...
iBio to Participate in the JMP Securities Life Sciences Conference
May 09, 2023 16:30 ET
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its...
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
April 04, 2023 16:05 ET
|
iBio, Inc.
BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given...
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
March 31, 2023 08:10 ET
|
iBio, Inc.
– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Treg depletion franchise beyond IBIO-101 – BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc....
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
February 16, 2023 16:48 ET
|
iBio, Inc.
- Company has directed antibodies against a specific region of MUC16 - - Potentially offers a differentiated and effective tool in the fight against cancer - BRYAN, Texas, Feb. 16, 2023 (GLOBE...